210 related articles for article (PubMed ID: 34180759)
61. CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma.
Jiang N; Niu G; Pan YH; Pan W; Zhang MF; Zhang CZ; Shen H
EBioMedicine; 2020 Mar; 53():102692. PubMed ID: 32113161
[TBL] [Abstract][Full Text] [Related]
62. Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma.
Rasti A; Abolhasani M; Zanjani LS; Asgari M; Mehrazma M; Madjd Z
J Cancer Res Clin Oncol; 2017 Jan; 143(1):95-104. PubMed ID: 27638770
[TBL] [Abstract][Full Text] [Related]
63. High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.
Lyu X; Li H; Ma X; Li X; Gao Y; Ni D; Shen D; Gu L; Wang B; Zhang Y; Zhang X
Cell Biochem Biophys; 2015 Jan; 71(1):279-90. PubMed ID: 25120023
[TBL] [Abstract][Full Text] [Related]
64. LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis.
Song EL; Xing L; Wang L; Song WT; Li DB; Wang Y; Gu YW; Liu MM; Ni WJ; Zhang P; Ma X; Zhang X; Yao J; Chen Y; An RH
Aging (Albany NY); 2019 Aug; 11(15):5705-5725. PubMed ID: 31400752
[TBL] [Abstract][Full Text] [Related]
65. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
[TBL] [Abstract][Full Text] [Related]
66. Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo.
Ji SQ; Yao L; Zhang XY; Li XS; Zhou LQ
J Exp Clin Cancer Res; 2012 Mar; 31(1):22. PubMed ID: 22420896
[TBL] [Abstract][Full Text] [Related]
67. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling.
Li JK; Chen C; Liu JY; Shi JZ; Liu SP; Liu B; Wu DS; Fang ZY; Bao Y; Jiang MM; Yuan JH; Qu L; Wang LH
Mol Cancer; 2017 Jun; 16(1):111. PubMed ID: 28659173
[TBL] [Abstract][Full Text] [Related]
68. MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition.
Shao Q; Zhang P; Ma Y; Lu Z; Meng J; Li H; Wang X; Chen D; Zhang M; Han Y; Liu H; Ma S
Gene; 2018 Apr; 652():48-58. PubMed ID: 29427737
[TBL] [Abstract][Full Text] [Related]
69. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
[TBL] [Abstract][Full Text] [Related]
70. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
71. [Biological effect of down-regulating of MTRR gene on cisplatin-resistant ovarian cancer SKOV3 cells in vitro and in vivo studies].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):126-34. PubMed ID: 26917482
[TBL] [Abstract][Full Text] [Related]
72. E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis.
Shen D; Gao Y; Huang Q; Xuan Y; Yao Y; Gu L; Huang Y; Zhang Y; Li P; Fan Y; Tang L; Du S; Wu S; Wang H; Wang C; Gong H; Pang Y; Ma X; Wang B; Zhang X
Cancer Lett; 2021 Aug; 514():48-62. PubMed ID: 34019961
[TBL] [Abstract][Full Text] [Related]
73. Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1-mediated translation of HIF1α in clear cell renal cell carcinoma.
Zhao P; Deng Y; Wu Y; Guo Q; Zhou L; Yang X; Wang C
FASEB J; 2021 Feb; 35(2):e21160. PubMed ID: 33150667
[TBL] [Abstract][Full Text] [Related]
74. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
75. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
[TBL] [Abstract][Full Text] [Related]
76. Cripto-1 expression in patients with clear cell renal cell carcinoma is associated with poor disease outcome.
Xue YJ; Chen SN; Chen WG; Wu GQ; Liao YF; Xu JB; Tang H; Yang SH; He SY; Luo YF; Wu ZH; Huang HW
J Exp Clin Cancer Res; 2019 Aug; 38(1):378. PubMed ID: 31455359
[TBL] [Abstract][Full Text] [Related]
77. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression.
Wu J; Chen H; Ye M; Wang B; Zhang Y; Sheng J; Meng T; Chen H
Biomed Pharmacother; 2019 Jul; 115():108869. PubMed ID: 31028999
[TBL] [Abstract][Full Text] [Related]
78. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.
Chen X; Wang X; Ruan A; Han W; Zhao Y; Lu X; Xiao P; Shi H; Wang R; Chen L; Chen S; Du Q; Yang H; Zhang X
Clin Cancer Res; 2014 May; 20(10):2617-30. PubMed ID: 24647573
[TBL] [Abstract][Full Text] [Related]
79. CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p.
Wang L; Yang G; Zhao D; Wang J; Bai Y; Peng Q; Wang H; Fang R; Chen G; Wang Z; Wang K; Li G; Yang Y; Wang Z; Guo P; Peng L; Hou D; Xu W
Mol Cancer; 2019 Apr; 18(1):86. PubMed ID: 30975145
[TBL] [Abstract][Full Text] [Related]
80. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Yan L; Ding B; Liu H; Zhang Y; Zeng J; Hu J; Yao W; Yu G; An R; Chen Z; Ye Z; Xing J; Xiao K; Wu L; Xu H
Theranostics; 2019; 9(26):8377-8391. PubMed ID: 31754403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
